---
title: "Tagraxofusp"
slug: "tagraxofusp"
date: "2023-11-20"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[Antibody Drug Conjugates]]

# Tagraxofusp

- Mechanism: Recombinant IL-3-diphtheria toxin fusion protein; internalization releases truncated diphtheria toxin, producing protein synthesis inhibition & cell death
- Approved indication: Blastic plasmacytoid dendritic cell neoplasm
- Dosing: 12 mcg/kg IV d 1-5 of 21-d cycles; do not dose after cycle d 10 if doses delayed for toxicity; hold if AST &/or AST >5Ã— ULN, &/or if creatinine >1.8 mg/dL or creatinine clearance <60 mL/min; additional hold criteria in package insert
- PK/PD: T1/2 0.7 h
- AEs: Capillary leak syndrome (BBW), hypersensitivity rxns, transaminitis, myelosuppression (20% febrile neutropenia), hyperglycemia, low vomiting risk
- DDI: No DDI studies conducted
- Clinical pearls:
  - Manufacturer-recommended monitoring & management of capillary leak,
  - including predose parameters for administration,
  - available; first cycle must be inpt;
  - premedicate each dose w/
    - H1RA,
    - H2RA,
    - acetaminophen,
    - & corticosteroid
